---
title: Pharmaceutical industry economics and innovation
videoId: EixhVBV2yzo
---

From: [[acquiredfm]] <br/> 

The pharmaceutical industry is characterized by its immense complexity <a class="yt-timestamp" data-t="00:03:38">[00:03:38]</a>. Historically, it operated before regulatory bodies like the Food and Drug Administration (FDA), significant industry consolidation, or healthcare oligopolies <a class="yt-timestamp" data-t="00:03:46">[00:03:46]</a>, and prior to the widespread availability of modern treatments such as antibiotics and vaccines <a class="yt-timestamp" data-t="00:03:52">[00:03:52]</a>.

## Historical Context: Insulin and Early Pharma

The discovery and extraction of insulin in 1921 at the University of Toronto Medical School marked a pivotal moment in modern medicine <a class="yt-timestamp" data-t="00:05:31">[00:05:31]</a>. Insulin, a hormone that regulates glucose absorption, is crucial for metabolic health <a class="yt-timestamp" data-t="00:05:46">[00:05:46]</a>. Its insufficiency leads to diabetes <a class="yt-timestamp" data-t="00:05:56">[00:05:56]</a>. The initial discovery involved Frederick Banting, Charles Best, and John McLoud <a class="yt-timestamp" data-t="00:06:08">[00:06:08]</a>, with Banting and McLoud receiving the 1923 Nobel Prize in Physiology or Medicine <a class="yt-timestamp" data-t="00:06:40">[00:06:40]</a>.

At the time, Type 1 diabetes was a common "death sentence" with no effective treatment beyond a "starvation diet" designed to prolong life <a class="yt-timestamp" data-t="00:07:06">[00:07:06]</a>, <a class="yt-timestamp" data-t="00:08:08">[00:08:08]</a>. The isolation of insulin was hailed as one of the most important advances in modern medicine <a class="yt-timestamp" data-t="00:08:35">[00:08:35]</a>.

Despite its miraculous effects, insulin was not a cure, requiring regular injections (initially every few hours) to sustain life <a class="yt-timestamp" data-t="00:10:56">[00:10:56]</a>. Early insulin was also impure, causing side effects like swelling and infections <a class="yt-timestamp" data-t="00:43:46">[00:43:46]</a>, and was not shelf-stable in liquid form <a class="yt-timestamp" data-t="00:43:57">[00:43:57]</a>, requiring patients to dissolve solid tablets before injection <a class="yt-timestamp" data-t="00:44:07">[00:44:07]</a>.

### Commercialization Challenges and Early Innovation

Initially, there was a perception that it was unethical to commercialize medical breakthroughs <a class="yt-timestamp" data-t="00:12:21">[00:12:21]</a>. However, the immense global demand for insulin led the University of Toronto to license production rights to Eli Lilly in 1921 <a class="yt-timestamp" data-t="00:13:14">[00:13:14]</a>, making them a leading American and international pharmaceutical company <a class="yt-timestamp" data-t="00:16:16">[00:16:16]</a>. Eli Lilly innovated by sourcing animal pancreases from slaughterhouses for mass production <a class="yt-timestamp" data-t="00:14:15">[00:14:15]</a> and developed a brand around insulin <a class="yt-timestamp" data-t="00:15:53">[00:15:53]</a>.

The early development of insulin was constrained by the need for animal pancreases:
*   It took 8,000 pounds of pancreatic glands from 23,500 animals to make a single pound of human insulin <a class="yt-timestamp" data-t="00:26:11">[00:26:11]</a>.
*   By 1980, 1 million animals were required annually for only 30,000 diabetes patients <a class="yt-timestamp" data-t="00:26:27">[00:26:27]</a>. This limitation meant that Type 2 diabetes was not treated with insulin <a class="yt-timestamp" data-t="00:14:12">[01:14:12]</a>.

### [[product_development_during_economic_challenges | Product Development During Economic Challenges]] and Competition

In Denmark, August Krogh, a Nobel Prize winner, facilitated the establishment of Nordisk Insulin in 1924, driven by his wife's diabetes diagnosis <a class="yt-timestamp" data-t="00:19:12">[00:19:12]</a>, <a class="yt-timestamp" data-t="00:33:12">[00:33:12]</a>. This company was unique, being 100% owned and controlled by a nonprofit foundation with a dual mission:
1.  Produce and sell insulin at cost in Scandinavia to maximize public health benefit <a class="yt-timestamp" data-t="00:35:50">[00:35:50]</a>.
2.  Export at market prices and use profits to fund diabetes research <a class="yt-timestamp" data-t="00:36:04">[00:36:04]</a>.
This foundation structure, common in Danish companies like Lego and Maersk, significantly influenced the company's long-term product development and market strategy <a class="yt-timestamp" data-t="00:34:20">[00:34:20]</a>, <a class="yt-timestamp" data-t="00:35:05">[00:35:05]</a>.

Bitter competition emerged with the founding of Novo in 1925 by former Nordisk employees <a class="yt-timestamp" data-t="00:40:40">[00:40:40]</a>, spurred by the inability to patent drugs in Denmark <a class="yt-timestamp" data-t="00:40:14">[00:40:14]</a>. Novo introduced shelf-stable liquid insulin, selling it at half the price of Nordisk's tablets, forcing innovation <a class="yt-timestamp" data-t="00:47:23">[00:47:23]</a>. Nordisk responded with longer-lasting protamine insulin (NPH) <a class="yt-timestamp" data-t="00:48:26">[00:48:26]</a>, which was widely licensed, but specifically withheld from Novo <a class="yt-timestamp" data-t="00:49:03">[00:49:03]</a>.

During World War II, Novo leveraged the German occupation of Denmark to expand production and become Europe's dominant insulin producer, supplying Nazi-occupied Europe <a class="yt-timestamp" data-t="00:53:42">[00:53:42]</a>. Nordisk's licensing revenue from Allied countries ceased <a class="yt-timestamp" data-t="00:53:57">[00:53:57]</a>. After the war, the Danish state required Novo to repay most wartime profits <a class="yt-timestamp" data-t="00:55:46">[00:55:46]</a>. Novo continued to innovate, developing slower-acting "Lent" insulin for basal needs <a class="yt-timestamp" data-t="00:57:07">[00:57:07]</a> and later, pure "MC insulin" <a class="yt-timestamp" data-t="00:59:50">[00:59:50]</a>.

## [[american_economic_policy_and_industrial_innovation | American Economic Policy and Industrial Innovation]] and Modern Pharma

The landscape of the pharmaceutical industry changed dramatically in the 1980s with the rise of Type 2 diabetes and the advent of genetic engineering <a class="yt-timestamp" data-t="01:09:04">[01:09:04]</a>. The number of Type 2 diabetes patients quadrupled from 1980 to 2016 <a class="yt-timestamp" data-t="01:13:38">[01:13:38]</a>.

### The Biotech Revolution and [[role_of_technology_and_innovation_in_venture_capital_and_startups | Role of Technology and Innovation in Venture Capital and Startups]]

In 1980, [[role_of_technology_and_innovation_in_venture_capital_and_startups | Genentech]], a [[venture_capital_industry_dynamics | venture capital industry dynamics]]-backed company, partnered with Eli Lilly to produce the first genetically engineered human insulin through recombinant DNA technology <a class="yt-timestamp" data-t="01:14:46">[01:14:46]</a>, revolutionizing drug production and making human insulin chemically identical to the body's natural form <a class="yt-timestamp" data-t="01:15:33">[01:15:33]</a>. This was a manufacturing and scale advantage rather than a significant efficacy gain <a class="yt-timestamp" data-t="01:16:04">[01:16:04]</a>.

The announcement sparked a "race for human insulin" <a class="yt-timestamp" data-t="01:16:33">[01:16:33]</a> and immense investor excitement, with Genentech's 1980 IPO being the largest venture-backed IPO at the time, only to be surpassed by Apple's two months later <a class="yt-timestamp" data-t="01:18:42">[01:18:42]</a>. Novo's attempt to chemically modify pig insulin into human insulin failed <a class="yt-timestamp" data-t="01:17:11">[01:17:11]</a>.

### Industry Consolidation and the Healthcare Value Chain

The late 1980s and early 1990s saw massive consolidation in the pharmaceutical industry, emphasizing the need for scale in R&D, clinical trials, and market negotiation <a class="yt-timestamp" data-t="01:21:10">[01:21:10]</a>.

The US healthcare value chain is exceptionally complex:
*   **Manufacturers:** Develop and produce drugs, conduct clinical trials <a class="yt-timestamp" data-t="01:25:57">[01:25:57]</a>.
*   **Distributors/Wholesalers:** Buy, warehouse, and distribute drugs to pharmacies <a class="yt-timestamp" data-t="01:26:13">[01:26:13]</a>.
*   **Pharmacies:** Dispense drugs to consumers <a class="yt-timestamp" data-t="01:26:27">[01:26:27]</a>. Major chains like CVS Caremark and Walgreens Boots Alliance also have integrated Pharmacy Benefit Managers (PBMs) <a class="yt-timestamp" data-t="01:26:30">[01:26:30]</a>.
*   **Pharmacy Benefit Managers (PBMs):** Negotiate discounts and rebates with manufacturers on behalf of insurance companies, covering 266 million Americans <a class="yt-timestamp" data-t="01:24:37">[01:24:37]</a>, <a class="yt-timestamp" data-t="01:28:12">[01:28:12]</a>. Three major PBMs control about 80% of the market (Express Scripts, CVS Caremark, OptumRx) <a class="yt-timestamp" data-t="01:28:24">[01:28:24]</a>. PBMs act as gatekeepers; pharmaceutical companies generally need their drugs on all three major formularies to be viable <a class="yt-timestamp" data-t="01:28:51">[01:28:51]</a>. Rebates can account for a significant portion (e.g., Eli Lilly claimed 75%) of the sticker price of drugs <a class="yt-timestamp" data-t="01:30:32">[01:30:32]</a>.
*   **Insurance Companies:** Pay for prescriptions, often outsourcing negotiation to PBMs <a class="yt-timestamp" data-t="01:24:06">[01:24:06]</a>.
*   **Employers:** Often involved in health plan choices <a class="yt-timestamp" data-t="01:24:55">[01:24:55]</a>.

This multi-layered system creates friction and distorts demand signals, making a "functioning market" difficult <a class="yt-timestamp" data-t="01:25:31">[01:25:31]</a>. In the US, average job tenure (3.7 years) means private insurers have short time horizons, disincentivizing coverage of long-term preventative care like obesity drugs, as costs may be offloaded to future insurers or Medicare <a class="yt-timestamp" data-t="02:28:30">[02:28:30]</a>. Medicare Part D (prescription drug coverage for those over 65), passed in 2003, is legally prohibited from paying for weight loss drugs <a class="yt-timestamp" data-t="02:30:42">[02:30:42]</a>, partly due to historical stigma <a class="yt-timestamp" data-t="02:31:12">[02:31:12]</a>.

## The Glucagon-Like Peptide-1 (GLP-1) Revolution

In 1989, Novo Nordisk scientist Lotte Bjerre Knudsen began researching Glucagon-Like Peptide-1 (GLP-1), a hormone disrupted in Type 2 diabetes <a class="yt-timestamp" data-t="01:45:00">[01:45:00]</a>. Despite initial industry skepticism due to GLP-1's short half-life (5 minutes), Knudsen's team developed Liraglutide, a GLP-1 analog with a 13-hour half-life, by grafting a fatty acid onto the molecule to prevent its breakdown <a class="yt-timestamp" data-t="01:49:01">[01:49:01]</a>.

In 2005, the world's first GLP-1 analog drug, Byetta, was launched by Eli Lilly, derived from a hormone found in Gila monster lizard venom <a class="yt-timestamp" data-t="01:51:10">[01:51:10]</a>. However, Byetta required two daily injections and was not overwhelmingly more effective than existing oral anti-diabetics <a class="yt-timestamp" data-t="01:54:40">[01:54:40]</a>.

Novo Nordisk's Liraglutide (marketed as Victoza for diabetes) launched in 2010 <a class="yt-timestamp" data-t="02:08:05">[02:08:05]</a>. It became a "Blockbuster" drug, exceeding $1 billion in annual sales in its first full year <a class="yt-timestamp" data-t="02:08:51">[02:08:51]</a>. Its "off-label" use for weight loss (a physician's discretion) was widespread <a class="yt-timestamp" data-t="02:09:53">[02:09:53]</a>.

Despite this, the obesity drug market was tiny, with annual sales of only $744 million until 2020 <a class="yt-timestamp" data-t="02:03:10">[02:03:10]</a>. This was due to a strong stigma against weight loss drugs (often seen as a personal responsibility issue) <a class="yt-timestamp" data-t="02:00:52">[02:00:52]</a> and a history of dangerous or ineffective products like Fen-Phen, which caused major heart damage <a class="yt-timestamp" data-t="02:01:32">[02:01:32]</a>. Researchers also believed it was impossible to create a safe and effective weight loss drug <a class="yt-timestamp" data-t="02:01:28">[02:01:28]</a>.

In 2007, Novo Nordisk, against its CEO's previous public stance that "obesity is primarily a social and cultural problem" <a class="yt-timestamp" data-t="02:04:14">[02:04:14]</a>, began human trials for a higher dose Liraglutide for weight loss <a class="yt-timestamp" data-t="02:06:11">[02:06:11]</a>. This version, Saxenda, launched in 2014, but only achieved an average of 8% BMI reduction, below the "magical 10% threshold" needed for market tipping <a class="yt-timestamp" data-t="02:12:01">[02:12:01]</a>.

The true breakthrough came with Semaglutide (Ozempic for diabetes, Wegovy for weight loss), which entered Phase 3 trials in 2016 <a class="yt-timestamp" data-t="02:14:53">[02:14:53]</a>. Semaglutide offered significant advantages:
*   Once-weekly injection due to a much longer half-life <a class="yt-timestamp" data-t="02:15:34">[02:15:34]</a>.
*   Twice as effective for weight loss as Liraglutide, achieving 15%+ BMI reduction, exceeding the 10% "magical threshold" <a class="yt-timestamp" data-t="02:15:54">[02:15:54]</a>.

Semaglutide works by impacting brain signals related to satiety and slowing digestion <a class="yt-timestamp" data-t="02:16:46">[02:16:46]</a>, leading to reduced food intake. Common side effects include nausea and constipation <a class="yt-timestamp" data-t="02:17:41">[02:17:41]</a>, with about one in six patients discontinuing due to severity <a class="yt-timestamp" data-t="02:17:54">[02:17:54]</a>.

Ozempic launched in 2018, hitting $1 billion in revenue in its first year <a class="yt-timestamp" data-t="02:19:24">[02:19:24]</a>. Wegovy, the official weight loss version, was approved in 2021. Within its first month, Wegovy had the same number of prescriptions as Saxenda had in its entire lifetime <a class="yt-timestamp" data-t="02:21:07">[02:21:07]</a>, being hailed as a "GameChanger" by the New York Times <a class="yt-timestamp" data-t="02:21:42">[02:21:42]</a>.

As a result, Novo Nordisk's market cap surged, reaching half a trillion dollars, making it Europe's largest company <a class="yt-timestamp" data-t="02:22:44">[02:22:44]</a>. By 2023, 69% of their revenue came from GLP-1 drugs <a class="yt-timestamp" data-t="02:28:31">[02:28:31]</a>.

### Pricing and Access in the US Healthcare System

In the US, Ozempic costs over $1,000/month, and Wegovy over $1,300/month, before insurance <a class="yt-timestamp" data-t="02:27:30">[02:27:30]</a>. In contrast, Ozempic costs $147/month in Canada and $93/month in the UK <a class="yt-timestamp" data-t="02:27:47">[02:27:47]</a>. Despite high sticker prices, many insured patients pay around $300/month due to co-pays <a class="yt-timestamp" data-t="02:38:00">[02:38:00]</a>. However, high costs and supply constraints create significant access problems <a class="yt-timestamp" data-t="02:38:50">[02:38:50]</a>, alongside high non-adherence rates (68% drop off after a year) <a class="yt-timestamp" data-t="02:39:10">[02:39:10]</a>.

Other major pharma companies like Eli Lilly have also developed competing GLP-1 drugs, such as Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), which bundles GLP-1 with another hormone (GIP) for potentially greater efficacy <a class="yt-timestamp" data-t="02:35:11">[02:35:11]</a>. This competition is expected to drive further innovation, similar to the historical insulin market <a class="yt-timestamp" data-t="02:36:05">[02:36:05]</a>.

## Economics of Pharma: Risk, Returns, and Power

The pharmaceutical industry is inherently high-risk, high-return, resembling [[venture_capital_industry_dynamics | venture capital industry dynamics]] but with even longer investment horizons (over a decade for R&D) <a class="yt-timestamp" data-t="03:11:51">[03:11:51]</a>. On average, bringing a drug to market costs $2.5 billion <a class="yt-timestamp" data-t="03:11:03">[03:11:03]</a>.
*   Only 10% of drugs entering clinical development make it to market <a class="yt-timestamp" data-t="03:12:41">[03:12:41]</a>.
*   The top 1% of drugs generate half of an industry's profits <a class="yt-timestamp" data-t="03:12:59">[03:12:59]</a>.
*   Most approved drugs do not even earn back their R&D costs <a class="yt-timestamp" data-t="03:13:02">[03:13:02]</a>.

This risk profile drives consolidation, as only large companies can afford to fund extensive drug pipelines <a class="yt-timestamp" data-t="03:13:16">[03:13:16]</a>.

### Porter's Five Forces and "Seven Powers"

In the pharmaceutical industry, several "powers" (as defined by Hamilton Helmer) contribute to persistent differential positive returns:
*   **Cornered Resource (Patents):** Pharma is a patent-driven industry <a class="yt-timestamp" data-t="02:45:43">[02:45:43]</a>. Novo Nordisk holds the patent on Semaglutide until 2032 <a class="yt-timestamp" data-t="02:45:48">[02:45:48]</a>. Patents cover molecules and delivery mechanisms <a class="yt-timestamp" data-t="02:47:25">[02:47:25]</a>. The GLP-1 supercycle is expected to involve "ever stacking waves of patentable innovation" <a class="yt-timestamp" data-t="02:46:52">[02:46:52]</a>.
*   **Scale Economies:** Apply across R&D, production, and go-to-market strategies <a class="yt-timestamp" data-t="02:48:42">[02:48:42]</a>. Large companies have an advantage in negotiating with PBMs and distributors <a class="yt-timestamp" data-t="02:48:05">[02:48:05]</a>.
*   **Switching Costs:** Once a patient finds a drug that works, they are unlikely to change due to the inconvenience and potential for regression (e.g., weight regain if GLP-1 treatment stops) <a class="yt-timestamp" data-t="02:51:32">[02:51:32]</a>.
*   **Branding:** While not typical for pharma, Ozempic has achieved significant brand recognition, contributing to its widespread adoption and perceived superiority <a class="yt-timestamp" data-t="02:49:26">[02:49:26]</a>.
*   **Network Economies:** GLP-1 drugs for weight loss, due to their visible effects, function somewhat like consumer tech products with tight feedback loops and "word of mouth" marketing <a class="yt-timestamp" data-t="02:51:58">[02:51:58]</a>, as users effectively become "walking billboards" <a class="yt-timestamp" data-t="02:53:17">[02:53:17]</a>.

### [[economic_and_policy_dynamics_of_the_us_healthcare_system | Economic and Policy Dynamics of the US Healthcare System]]

The US healthcare system is highly expensive, consuming 17-18% of GDP, up from 5% in 1960 <a class="yt-timestamp" data-t="03:14:16">[03:14:16]</a>. Despite this, life expectancy has declined <a class="yt-timestamp" data-t="03:16:26">[03:16:26]</a>. The system was originally designed to treat acute and infectious diseases <a class="yt-timestamp" data-t="03:18:58">[03:18:58]</a>, and is now struggling with chronic illnesses that require different approaches, such as preventative care <a class="yt-timestamp" data-t="03:19:42">[03:19:42]</a>.

While Pharma companies incur significant R&D risks and costs, often leading to spiky net income, insurance companies, by contrast, tend to have consistently stable profits <a class="yt-timestamp" data-t="03:29:08">[03:29:08]</a>. The administrative costs of health insurance (8% of a very large number) are comparable to the total revenue of the Pharma sector (13% of healthcare revenue) <a class="yt-timestamp" data-t="03:26:52">[03:26:52]</a>, <a class="yt-timestamp" data-t="03:28:37">[03:28:37]</a>. This leads to questions about value capture and allocation within the system, with many perceiving that the healthcare system is "broken" <a class="yt-timestamp" data-t="03:14:31">[03:14:31]</a>.

## Playbook and Future Outlook

Novo Nordisk's success is attributed to its extreme concentration: 85% of revenue is from metabolic disorders <a class="yt-timestamp" data-t="02:56:50">[02:56:50]</a>. This focus allowed them to build deep expertise and pursue long-term research, leading to breakthroughs like GLP-1s, despite industry trends towards specialized, high-priced drugs for rare diseases <a class="yt-timestamp" data-t="03:07:32">[03:07:32]</a>. The Novo Nordisk Foundation's governance structure, which prioritizes "stability and supporting scientific and humanitarian causes" over mere growth <a class="yt-timestamp" data-t="03:27:57">[03:27:57]</a>, also played a crucial role in enabling long-term investments and preventing the company's acquisition <a class="yt-timestamp" data-t="01:39:50">[01:39:50]</a>.

The company's executives are not primarily incentivized by stock price performance, fostering a different, longer-term time horizon <a class="yt-timestamp" data-t="03:03:53">[03:03:53]</a>. The Novo Nordisk Foundation, with assets worth $120 billion, is the largest charitable foundation globally, actively investing in life sciences and biotech <a class="yt-timestamp" data-t="02:59:48">[02:59:48]</a>.

The bull case for Novo Nordisk is the potential for GLP-1s to be the next "super cycle" in pharma, with demand far outstripping supply <a class="yt-timestamp" data-t="03:33:35">[03:33:35]</a>. Semaglutide is already showing promise for treating cardiovascular disease, Alzheimer's, and kidney disease <a class="yt-timestamp" data-t="02:26:19">[02:26:19]</a>. The demand is so vast that multiple companies, including Eli Lilly, can be highly successful in this market <a class="yt-timestamp" data-t="02:36:05">[02:36:05]</a>.

The bear case involves potential long-term health risks (e.g., loss of lean muscle mass) or a lack of sustained efficacy <a class="yt-timestamp" data-t="03:35:50">[03:35:50]</a>, or that the market might not sustain its current multi-decade growth trajectory <a class="yt-timestamp" data-t="03:34:04">[03:34:04]</a>.